Prescient Surgical has been awarded a group purchasing agreement for a Breakthrough Technology contract with Premier. Effective November 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the CleanCision Wound Retraction and Protection device, the first in a new class of advanced technology that fights and defends against the sources of surgical site infection (SSI).
“We are thrilled to be recognized by Premier as a Breakthrough Technology and are excited about the opportunity to introduce CleanCision to Premier’s member hospitals,” commented Jonathan Coe, the company’s founder and CEO. “This contract establishes critical infrastructure to scale our commercialization efforts and accelerate CleanCision’s adoption by a wider range of surgeons.”
SSI, especially in abdominal surgery, is a constant threat to patients and hospitals. It is estimated that 3 out of 20 patients undergoing high-risk abdominal surgery will develop an infection.1, 2, 3 CleanCision was designed by surgeons and infection control experts to help hospitals gain control over the sources of SSI. Unlike traditional methods, which cannot continuously and consistently clear contamination from the surgical site, CleanCision utilizes active cleansing technology to clear harmful bacteria that may invade the incision during surgery when the threat of wound contamination is at its highest. In clinical studies, CleanCision has been shown to reduce the risk of SSI in high risk abdominal surgeries by 61-100% compared to existing standard of care preventative measures.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,100 U.S. hospitals and 200,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
